Polypoidal Choroidal Vasculopathy Clinical Trial
Official title:
An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.
Efficacy of VEGF Trap-Eye (aflibercept, Eylea) for exudative age-related macular degeneration (AMD) was demonstrated in the phase III VIEW study. Polypoidal choroidal vasculopathy (PCV) is considered as a subtype of exudative AMD, however it is reportedly different from choroidal new vessels based on the histologic studies. The aim of this study is to evaluate effects of VEGF Trap-Eye in treatment of PCV, which was diagnosed using indocyanine green (ICG) angiography. VEGF Trap-Eye will be injected intravitreally bimonthly after 3 monthly loading dose for 12 months in treatment-naive PCV patients. The efficacy will be evaluated on preserving visual acuity and improving angiographic features at 12 months. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT01469156 -
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT02597855 -
Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography
|
N/A | |
Completed |
NCT02495181 -
Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Active, not recruiting |
NCT02976194 -
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Recruiting |
NCT01248117 -
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01884597 -
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04707027 -
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
|
N/A | |
Recruiting |
NCT02141308 -
OCT in Rare Chorioretinal Diseases
|
||
Completed |
NCT01871376 -
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
|
Phase 4 | |
Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT00383812 -
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
|
N/A | |
Completed |
NCT00837330 -
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Completed |
NCT05229237 -
Conbercept for Polypoidal Choroidal Vasculopathy(START Study)
|
||
Not yet recruiting |
NCT04380974 -
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Recruiting |
NCT02815176 -
Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers
|
N/A | |
Active, not recruiting |
NCT00344617 -
Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
|
Phase 3 | |
Recruiting |
NCT03929731 -
Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
|
||
Completed |
NCT01023295 -
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
|
Phase 2 | |
Completed |
NCT02821520 -
Initial Versus Delayed PDT Combination With Conbercept in PCV
|
Phase 4 |